ClearPoint Neuro (NASDAQ:CLPT) Issues Earnings Results, Beats Estimates By $0.08 EPS

ClearPoint Neuro (NASDAQ:CLPT) announced its quarterly earnings results on Wednesday. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.08, FiscalAI reports. The company had revenue of $12.07 million for the quarter, compared to analyst estimates of $12.30 million. ClearPoint Neuro had a negative net margin of 79.43% and a negative return on equity of 188.08%.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• Third-quarter revenue rose 36% year over year to $12.1 million, led by 59% growth in neurosurgery navigation revenue and 68% growth in capital equipment and software revenue, including contributions from IRRAflow.
• ClearPoint reported its largest-ever capital sales quarter and cited a record pipeline of hospitals preparing for cell and gene therapy trials. Management expects multiple partner Phase III trials to initiate or expand over the next 12–15 months.
• UniQure’s AMT-130 Huntington’s disease gene therapy remains a major potential catalyst; if the FDA accepts the BLA and the review proceeds successfully, ClearPoint expects to pursue a companion 510(k) with possible commercial approval in mid-to-late 2027.
• Gross margin declined to 58% from 63% because of start-up overhead at ClearPoint Advanced Laboratories and amortization from acquired intangible assets. The company also used its ATM facility to raise $22 million, creating shareholder dilution, while reporting $20.1 million of operational cash burn through the first nine months.
• Management expects continued front-loaded investment in the CAL facility, IRRAflow product launches, robotics, focused ultrasound, and clinical staffing, although it expects operating leverage to gradually reduce cash burn over the next four to six quarters. The company characterized mid-teens revenue growth as a reasonable early view for 2027 but has not issued formal guidance.

ClearPoint Neuro Trading Up 1.2%

NASDAQ:CLPT opened at $10.69 on Friday. ClearPoint Neuro has a 12-month low of $8.27 and a 12-month high of $24.98. The firm has a market cap of $326.05 million, a P/E ratio of -8.83 and a beta of 1.29. The company has a current ratio of 4.74, a quick ratio of 3.89 and a debt-to-equity ratio of 4.66. The stock’s 50 day simple moving average is $12.60 and its 200-day simple moving average is $13.02.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Thursday, October 15th. Stifel Nicolaus decreased their price objective on shares of ClearPoint Neuro from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday. Lake Street Capital set a $25.00 price objective on ClearPoint Neuro in a report on Tuesday, August 4th. Finally, Wall Street Zen cut ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, ClearPoint Neuro has an average rating of “Hold” and a consensus price target of $24.33.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes platforms for minimally invasive procedures involving the brain. Its technology is designed to help physicians plan, navigate and deliver treatments with real-time magnetic resonance imaging (MRI) guidance, supporting more precise access to targeted areas of the brain.

The company’s principal product is the ClearPoint Neuro Navigation System, which uses specialized software, instruments and accessories to guide neurosurgical procedures inside an MRI scanner.